Sr. AD, Public Policy (Ridgefield, CT, United States, Connecticut)

Description

The Sr. AD, Public Policy will advance Boehringer Ingelheim’s public policy agenda to improve patient access, enhance affordability, and support medical innovation. Create and execute public policy strategies to advance proprietary Boehringer business objectives related to our therapeutic areas. Provide expert analysis of government policy developments, assess potential impact on Boehringer therapeutic areas, identify opportunities, and mitigate risks.

As an employee of Boehringer Ingelheim, you will actively contribute to the discovery, development and delivery of our products to our patients and customers. Our global presence provides opportunity for all employees to collaborate internationally, offering visibility and opportunity to directly contribute to the companies´ success. We realize that our strength and competitive advantage lie with our people. We support our employees in a number of ways to foster a healthy working environment, meaningful work, mobility, networking and work-life balance. Our competitive compensation and benefit programs reflect Boehringer Ingelheim´s high regard for our employees.

Compensation Data

The base salary range for this position is $196,000 to $294,000. The position may be eligible for a role-specific discretionary bonus, relocation assistance, and/or other compensation elements. We continuously review market data and may adjust salary ranges as needed in the future. Actual compensation will be based on job-related factors such as skills, experience, qualifications, and other factors permitted by law. Benefits include medical, dental, and vision coverage, retirement savings opportunities, paid time off, paid holidays, disability and life insurance benefits, and other company-sponsored benefits. For additional information regarding our benefits and Total Rewards offerings, please click here.

Duties & Responsibilities

Identify, build, and execute a variety of strategies and tactics to advance Boehringer’s therapeutic area goals across federal and state governments as well as key Agencies (e.g., CMS, HHS, CMMI).

Represent the Public & Government Affairs (PGA) team on select therapeutic area extended brand teams and other cross-functional teams (payer, healthcare professional, patient) to align strategies with corporate objectives.

Monitor, analyze, and interpret legislative and regulatory policy developments relevant to Boehringer’s therapeutic areas.

Collaborate with internal brand teams and other business partners to develop key therapeutic area materials (e.g., policy briefs, toolkits, talking points, and other advocacy materials) for state and federal colleague utilization; and coordinate and complete the internal approval processes.

Develop Boehringer policy positions on key pharmaceutical and related public policy topics. Monitor, evaluate, and prioritize legislative and regulatory proposals relevant to these topics. Identify emerging trends, risks, and opportunities; conduct impact assessments; and recommend strategic actions.

Represent Boehringer in industry trade associations, coalitions, and working groups to advance priority issues. Build and sustain effective relationships with external stakeholders to strengthen the company’s advocacy efforts.

Requirements

Bachelor´s degree from an accredited institution required.

Graduate degree preferred.

A minimum of seven (7) years combined experience in government affairs in private industry, government, or a consultant firm in pharmaceuticals/health care is required.

Experience working on cross-functional teams addressing public policy issues.

Experience with projects supporting business objectives.

Knowledge of pharmaceutical industry and related public policy issues is required.

Requires advanced knowledge of state and federal government affairs and public policy, including policy analysis and government relations.

Desired Experience, Skills, and Abilities:

Experience analyzing health care proposals, identifying key provisions, and assessing impact on pharmaceutical industry is desired.